Connection

Chadrick Denlinger to Protein Kinase Inhibitors

Back to Details
This is a "connection" page, showing publications Chadrick Denlinger has written about Protein Kinase Inhibitors.
Chadrick Denlinger
Connection Strength
0.828
Protein Kinase Inhibitors
  1. Neuropilin-2b facilitates resistance to tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021 08; 162(2):463-473.
    View in: PubMed
    Score: 0.584
  2. Commentary: Durable activity of a tyrosine kinase inhibitor in lung cancer. J Thorac Cardiovasc Surg. 2021 02; 161(2):446-447.
    View in: PubMed
    Score: 0.145
  3. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23.
    View in: PubMed
    Score: 0.099
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.